Lecture review

Lecture: Research on the overcoming resistance of photocontrol-activated anti-tumor prodrug based on clinical platinum drugs

Introduction to the speaker

Deng Zhiqin, professor, doctoral supervisor, Hongshen outstanding scholar, was selected for the national youth talent program. Mainly engaged in the research and development and mechanism research of new anti-tumor drugs, especially metal anti-tumor drugs. As the first author (including co-) he published 14 papers in journals such as Nature Chemistry, Nature Catalysis, Nature Synthesis, JACS, Biomaterials, etc., and won the 2023 Hong Kong Youth Scientist Award, the Chinese Chemistry Association Jingqing Chemistry Spark Award and other awards. He presided over the National Natural Science Foundation of China, Chongqing Overseas Talent Attraction Project, Chongqing Natural Science Foundation of China and other projects.

Key points of the lecture

This lecture focused on the innovative design of platinum-based anti-tumor drugs and focused on introducing a new tetravalent platinum photooxidant. Through its unique molecular engineering and photocontrol activation mechanism, the drug breaks through the limitations of traditional chemotherapy and photodynamic therapy, providing a new solution for tumor treatment. This technology transforms traditional platinum drugs into "photo-controlled prodrugs" through molecular design, and uses specific wavelengths of light to achieve space-time activation of drugs. This precise regulation not only significantly enhances the efficacy of local drugs in the tumor, but also minimizes damage to normal tissues, providing a new path to reduce systemic toxicity. Studies have shown that the photoactivation strategy has shown a balance of tumor inhibition and safety in animal models that are better than traditional platinum drugs.

In short, photo-activated platinum prodrugs represent a paradigm shift in platinum drug research and development, from "undifferential attack" to a new treatment system driven by precision medicine. This technology not only provides a breakthrough for overcoming the clinical dilemma of platinum drugs, but also may promote tumor treatment to enter an intelligent era of "time and space controllable and multi-therapeutic linkage". Follow-up research needs to further explore its synergistic mechanism with immunotherapy, and ultimately help tumor patients achieve longer survival benefits and higher quality of life.